Security key
74365A309
Protalix BioTherapeutics, Inc. - Common Stock (PLX)
CUSIP: 74365A309
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 553,115
- Total 13F value
- $1,287,709
- Share change
- -245,662
- SEC-reported price per share
- $2.33
- Number of holders
- 23
- Value change
- -$468,937
- Number of buys
- 9
- Number of sells
- 7
- Shares outstanding
- 80,610,558
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
23
Top holders
10
PLX full security history
Ownership snapshot
Full 13F holder table
Protalix BioTherapeutics, Inc. SEC filings
Protalix BioTherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74365A309
Recent filing periods:
Ownership snapshot
Top reported holders of PLX - Protalix BioTherapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
MAK Capital Fund LP
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 5%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
5%
MAK Capital Fund LP
4.5%
Gilad Mamlok
0%
MAK CAPITAL ONE LLC
4.4%
RENAISSANCE TECHNOLOGIES LLC
1.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
5%
|
$9,428,694
4,046,650 shares
|
$0 | 30 Jun 2026 |
| MAK Capital Fund LP |
13D/G
|
4.5%
|
$11,355,147
3,616,289 shares
|
-$3,244,593 | 24 Mar 2026 |
| Gilad Mamlok |
3/4/5
Sr. VP and CFO
|
0%
|
$7,770
3,631 shares
|
— | 24 Aug 2025 |
| MAK CAPITAL ONE LLC |
13F
Company
|
4.4%
|
$7,690,782
3,544,139 shares
|
— | 31 Mar 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
1.5%
|
$2,657,816
1,224,800 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
1.2%
|
$2,111,009
972,815 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
23
Shares
553,115
Rows available
23
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
100
Q2 2026 holders
23
Holder diff
-77
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend